Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 218

1.

Saliva secretory IgA antibodies against molds and mycotoxins in patients exposed to toxigenic fungi.

Chirigos MA, Jirillo E.

Immunopharmacol Immunotoxicol. 2005;27(1):185. No abstract available.

PMID:
15803870
2.
3.

[Hepatitis B virus (HBV) and the inflammatory/immune response. I. The natural environment of the antigen presentation and immunologic chaos induced by the virus].

Villarrubia VG, Alvarez-Mon M, Chirigos MA, Herrerías JM.

Rev Esp Enferm Dig. 1997 Dec;89(12):919-28. Review. Spanish.

PMID:
9494379
4.

Leukocyte Interleukin, Inj. (LI) augmentation of natural killer cells and cytolytic T-lymphocytes.

Chirigos MA, Talor E, Sidwell RW, Burger RA, Warren RP.

Immunopharmacol Immunotoxicol. 1995 May;17(2):247-64.

PMID:
7650289
5.

AM3, an adjuvant to hepatitis B revaccination in non-responder healthy persons.

Sánchez L, Peña E, Civantos A, Sada G, Alvarez MM, Chirigos MA, Villarrubia VG.

J Hepatol. 1995 Jan;22(1):119-21. No abstract available.

PMID:
7751580
6.

Antiviral and immunomodulating inhibitors of experimentally-induced Punta Toro virus infections.

Sidwell RW, Huffman JH, Barnard DL, Smee DF, Warren RP, Chirigos MA, Kende M, Huggins J.

Antiviral Res. 1994 Oct;25(2):105-22.

PMID:
7847873
7.

Differential antiviral activity of two TIBO derivatives against the human immunodeficiency and murine leukemia viruses alone and in combination with other anti-HIV agents.

Buckheit RW Jr, Germany-Decker J, Hollingshead MG, Allen LB, Shannon WM, Janssen PA, Chirigos MA.

AIDS Res Hum Retroviruses. 1993 Nov;9(11):1097-106.

PMID:
7508723
8.
9.

Significant anti-HIV activity of new modified polyanionic polymers in vitro.

Buckheit RW Jr, White EL, Shannon WM, Guerrero A, Pivel JP, Carrasco L, Leal JA, Chirigos MA.

Immunopharmacol Immunotoxicol. 1992;14(4):707-21.

PMID:
1294618
10.

Immunomodulators: current and future development and application.

Chirigos MA.

Thymus. 1992;19 Suppl 1:S7-20. Review.

PMID:
1585422
11.

A TIBO derivative, R82913, is a potent inhibitor of HIV-1 reverse transcriptase with heteropolymer templates.

White EL, Buckheit RW Jr, Ross LJ, Germany JM, Andries K, Pauwels R, Janssen PA, Shannon WM, Chirigos MA.

Antiviral Res. 1991 Oct;16(3):257-66.

PMID:
1725247
12.

Characterization of the promoter for the rat and human link protein gene.

Rhodes C, Savagner P, Line S, Sasaki M, Chirigos M, Doege K, Yamada Y.

Nucleic Acids Res. 1991 Apr 25;19(8):1933-9.

13.

Effect of imexon treatment on Friend virus complex infection using genetically defined mice as a model for HIV-1 infection.

Morrey JD, Warren RP, Okleberry KM, Burger RA, Chirigos MA, Sidwell RW.

Antiviral Res. 1991 Jan;15(1):51-65.

PMID:
2036000
14.

Imexon and biological response modifiers in murine models of AIDS.

Chirigos MA, Ussery MA, Black PL.

Int J Immunopharmacol. 1991;13 Suppl 1:33-41.

PMID:
1823906
15.

Inhibition of NK cell generation by Corynebacterium parvum.

Piccoli M, Santoni G, Santoni A, Frati L, Herberman RB, Chirigos MA.

Immunopharmacol Immunotoxicol. 1991;13(4):513-29.

PMID:
1723083
16.

Antiviral efficacy of Imexon in the Rauscher murine retrovirus AIDS model.

Chirigos MA, Ussery MA, Rankin JT Jr, Herrmann D, Bicker U, Black PL.

Immunopharmacol Immunotoxicol. 1990;12(1):1-21. No abstract available.

PMID:
1693633
17.

Report of the symposium on the use of intravenous gammaglobulin in adults infected with the human immunodeficiency virus.

De Simone C, Antonaci S, Chirigos M, Delia S, Di Fabio S, Good RA, Hadden JW, Jirillo E, Lockey R, Milazzo F, et al.

J Clin Lab Anal. 1990;4(4):313-7. Review.

PMID:
1697338
18.

Use of glucan and other immunopharmacological agents in the prevention and treatment of acute radiation injuries.

Patchen ML, Chirigos MA, Brook I.

Fundam Appl Toxicol. 1988 Nov;11(4):573-4. No abstract available.

PMID:
3229582
19.

Survey of newer biological response modifiers for possible use in radioprotection.

Chirigos MA, Patchen ML.

Pharmacol Ther. 1988;39(1-3):243-6. No abstract available.

PMID:
3200888
20.

Radioprotection by biological response modifiers alone and in combination with WR-2721.

Patchen ML, D'Alesandro MM, Chirigos MA, Weiss JF.

Pharmacol Ther. 1988;39(1-3):247-54. Review. No abstract available.

PMID:
2849129
21.

Augmentation of natural cell activity in tumor-bearing and normal mice by MVE-2.

Budzynski W, Chirigos M, Gruys E.

Cancer Immunol Immunother. 1987;24(3):253-8.

PMID:
3594488
22.

Immune response by biological response modifiers.

Chirigos MA, Schlick E, Budzynski W.

Cancer Detect Prev Suppl. 1987;1:385-97.

PMID:
3500779
23.

Cell regulatory and immunorestorative activity of picibanil (OK432).

Chirigos MA, Saito T, Talmadge JE, Budzynski W, Gruys E.

Cancer Detect Prev Suppl. 1987;1:317-28.

PMID:
3480058
24.

Antiproliferative activity of picolinic acid due to macrophage activation.

Ruffmann R, Schlick R, Chirigos MA, Budzynsky W, Varesio L.

Drugs Exp Clin Res. 1987;13(10):607-14.

PMID:
3428125
25.

Protein deficiency reduces natural antitumor immunity.

Ruffmann R, Schlick E, Tartaris T, Budzynski W, Chirigos MA.

Cancer Detect Prev Suppl. 1987;1:15-27.

PMID:
3121178
26.

[Protein deficiency, host defense and natural anti-tumor immunity].

Ruffmann R, Schlick E, Tartaris T, Chirigos MA.

Infusionsther Klin Ernahr. 1986 Apr;13(2):106-12. Review. German.

PMID:
3519454
27.

Biological response modifiers: regulators of the cellular immune system and adjuvants in antitumor therapy.

Chirigos MA, Schlick E, Saito T, Gruys E.

Methods Find Exp Clin Pharmacol. 1986 Jan;8(1):27-33.

PMID:
3486334
28.

Pharmacokinetic and therapeutic activity of polyinosinic-polycytidylic acid stabilized with poly-L-lysine in carboxymethylcellulose [poly(I,C)-LC].

Chirigos MA, Schlick E, Ruffmann R, Budzynski W, Sinibaldi P, Gruys E.

J Biol Response Mod. 1985 Dec;4(6):621-7.

PMID:
4087033
29.

Effects of poly(I,C)-LC on growth and differentiation of normal and malignant myelopoietic progenitor cells.

Schlick E, Bettens F, Ruffmann R, Chirigos MA, Hewetson P.

J Biol Response Mod. 1985 Dec;4(6):628-33.

PMID:
3878862
30.

Hyporesponsiveness to augmentation of murine natural killer cell activity in different anatomical compartments by multiple injections of various immunomodulators including recombinant interferons and interleukin 2.

Talmadge JE, Herberman RB, Chirigos MA, Maluish AE, Schneider MA, Adams JS, Philips H, Thurman GB, Varesio L, Long C, et al.

J Immunol. 1985 Oct;135(4):2483-91.

PMID:
2411797
31.

Role of organ-associated NK cells in decreased formation of experimental metastases in lung and liver.

Wiltrout RH, Herberman RB, Zhang SR, Chirigos MA, Ortaldo JR, Green KM Jr, Talmadge JE.

J Immunol. 1985 Jun;134(6):4267-75.

PMID:
3989307
32.
33.

Immunotherapeutic potential in murine tumor models of polyinosinic-polycytidylic acid and poly-L-lysine solubilized by carboxymethylcellulose.

Talmadge JE, Adams J, Phillips H, Collins M, Lenz B, Schneider M, Chirigos M.

Cancer Res. 1985 Mar;45(3):1066-72.

35.

Immunomodulatory effects in mice of polyinosinic-polycytidylic acid complexed with poly-L-lysine and carboxymethylcellulose.

Talmadge JE, Adams J, Phillips H, Collins M, Lenz B, Schneider M, Schlick E, Ruffmann R, Wiltrout RH, Chirigos MA.

Cancer Res. 1985 Mar;45(3):1058-65.

37.

Effects of protein depletion on NK cell cytotoxicity and bone marrow cellularity.

Ruffmann R, Schlick E, Tartaris T, Gruys E, Welker RD, Saito T, Chirigos MA.

Med Oncol Tumor Pharmacother. 1985;2(3):195-202.

PMID:
3934473
38.

Immunotherapeutic agents: their role in cellular immunity and their therapeutic potential.

Chirigos MA, Talmadge JE.

Springer Semin Immunopathol. 1985;8(4):327-46. No abstract available.

PMID:
3911464
39.

Comparison of immunomodulatory and immunotherapeutic properties of biologic response modifiers.

Talmadge JE, Chirigos MA.

Springer Semin Immunopathol. 1985;8(4):429-43. No abstract available.

PMID:
3879016
40.

Therapy of peritoneal murine cancer with biological response modifiers.

Salup RR, Herberman RB, Chirigos MA, Back T, Wiltrout RH.

J Immunopharmacol. 1985;7(4):417-36.

PMID:
3878855
41.

Modulation of myelopoiesis by CSF or CSF-inducing biological response modifiers.

Schlick E, Ruffmann R, Hartung K, Chirigos MA.

J Immunopharmacol. 1985;7(1):141-66.

PMID:
3874241
42.

Development of hyporesponsiveness of natural killer cells to augmentation of activity after multiple treatments with biological response modifiers.

Saito T, Ruffman R, Welker RD, Herberman RB, Chirigos MA.

Cancer Immunol Immunother. 1985;19(2):130-5.

PMID:
3845849
43.

Characterization of biological response modifier release by human monocytes cultured in suspension in serum-free medium.

Stevenson HC, Schlick E, Griffith R, Chirigos MA, Brown R, Conlon J, Kanapa DJ, Oldham RK, Miller P.

J Immunol Methods. 1984 May 25;70(2):245-55.

PMID:
6202795
44.

In vivo activation of macrophages but not natural killer cells by picolinic acid (PLA).

Ruffmann R, Welker RD, Saito T, Chirigos MA, Varesio L.

J Immunopharmacol. 1984;6(4):291-304.

PMID:
6527007
45.

Bimodal effects of MVE-2 on cytotoxic activity of natural killer cell and macrophage tumoricidal activities.

Piccoli M, Saito T, Chirigos MA.

Int J Immunopharmacol. 1984;6(6):569-76.

PMID:
6511143
46.

Biological characterization of MVE-2 and poly ICLC.

Schlick E, Welker R, Piccoli M, Ruffmann R, Chirigos M.

Prog Clin Biol Res. 1984;161:511-24. No abstract available.

PMID:
6483902
47.

Vaccine adjuvant effects, and immune response, to synthetic polymers MVE and poly ICLC.

Chirigos MA, Welker R, Schlick E, Saito T, Ruffmann R.

Prog Clin Biol Res. 1984;161:467-79. No abstract available.

PMID:
6483899
48.

Comparison of in vitro and in vivo modulation of myelopoiesis by biological response modifiers.

Schlick E, Hartung K, Chirigos MA.

Cancer Immunol Immunother. 1984;18(3):226-32.

PMID:
6334554
49.

Immunomodulation and therapeutic characterization of thymosin fraction five.

Talmadge JE, Uithoven KA, Lenz BF, Chirigos M.

Cancer Immunol Immunother. 1984;18(3):185-94.

PMID:
6239686

Supplemental Content

Loading ...
Support Center